PMID- 38148673
OWN - NLM
STAT- MEDLINE
DCOM- 20240215
LR  - 20240216
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 15
IP  - 5
DP  - 2024 Feb
TI  - Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 
      patients.
PG  - 386-393
LID - 10.1111/1759-7714.15202 [doi]
AB  - BACKGROUND: This study aimed to investigate the clinicopathological features and 
      prognostic indicators of primary pulmonary adenoid cystic carcinoma (PACC). 
      METHODS: Clinical data were collected from 64 primary PACC patients and analyzed 
      retrospectively at the Tianjin Medical University General Hospital, the West 
      China Hospital of Sichuan University, the First Affiliated Hospital of Guangxi 
      Medical University, and the Bishan Hospital of Chongqing Medical University from 
      January 2003 to August 2023. The 64 patients (28 males and 36 females) were aged 
      from 20 to 73 years, with a median age of 49 years and an average age of 
      49.3 years. RESULTS: Immunohistochemical staining showed that the tumors 
      expressed CK7, S-100 protein, CK5/6, CD117, and p63. Seven patients underwent 
      fluorescence in situ hybridization (FISH) testing and three were found to have 
      myeloblastosis (MYB) gene translocation. In total, 53 patients underwent surgery, 
      among whom 31 received only surgery and 22 received both surgery and 
      postoperative chemoradiotherapy. In addition, 10 patients received 
      chemoradiotherapy only, while one patient underwent treatment with traditional 
      Chinese medicine. The overall survival rates in the first, third, and fifth years 
      were 98.4%, 95.3%, and 87.5%, respectively. CONCLUSION: Prognostic analysis 
      revealed that age, tumor size, lymph node metastasis status, margin status, and 
      choice of treatment modality significantly influenced the patients' prognosis.
CI  - (c) 2023 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, 
      Ltd.
FAU - Tan, Xiang
AU  - Tan X
AD  - Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Xu, Tao
AU  - Xu T
AD  - Department of Thoracic Surgery, the Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
FAU - Shen, Wang
AU  - Shen W
AUID- ORCID: 0000-0002-9211-2901
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Lung Cancer Center, West China Tianfu Hospital, Sichuan University, Chengdu, 
      China.
FAU - Ai, Cheng
AU  - Ai C
AD  - Department of Cardiothoracic Surgery, Bishan Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhang, Weilin
AU  - Zhang W
AD  - Lung Cancer Center, West China Tianfu Hospital, Sichuan University, Chengdu, 
      China.
AD  - Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Tang, Xiaojun
AU  - Tang X
AUID- ORCID: 0000-0001-8757-0927
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Lung Cancer Center, West China Tianfu Hospital, Sichuan University, Chengdu, 
      China.
FAU - Luo, Feng
AU  - Luo F
AD  - Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Zhou, Qinghua
AU  - Zhou Q
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Lung Cancer Center, West China Tianfu Hospital, Sichuan University, Chengdu, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20231226
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Carcinoma, Adenoid Cystic/genetics/therapy
MH  - Retrospective Studies
MH  - In Situ Hybridization, Fluorescence
MH  - China
MH  - Prognosis
MH  - *Lung Neoplasms/pathology
PMC - PMC10864118
OTO - NOTNLM
OT  - lung cancer
OT  - pathology
OT  - primary pulmonary adenoid cystic carcinoma
COIS- No authors report any conflict of interest in this work.
EDAT- 2023/12/27 06:42
MHDA- 2024/02/15 06:43
PMCR- 2023/12/26
CRDT- 2023/12/27 02:33
PHST- 2023/12/05 00:00 [revised]
PHST- 2023/10/14 00:00 [received]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2024/02/15 06:43 [medline]
PHST- 2023/12/27 06:42 [pubmed]
PHST- 2023/12/27 02:33 [entrez]
PHST- 2023/12/26 00:00 [pmc-release]
AID - TCA15202 [pii]
AID - 10.1111/1759-7714.15202 [doi]
PST - ppublish
SO  - Thorac Cancer. 2024 Feb;15(5):386-393. doi: 10.1111/1759-7714.15202. Epub 2023 
      Dec 26.